Evidence map›Paper›PMID 36258012›Full record

ArticleScientific reports2022

Using

Farshid Tabbakh, Narayan S Hosmane, Suffian M Tajudin, Amir-Hossein Ghorashi, Nader Morshedian

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Microdosimetric Simulation of Gold-Nanoparticle-Enhanced Radiotherapy.International journal of molecular sciences · 2024
    Article
  4. Study of Nuclear Reactions in Therapy of Tumors with Proton Beams.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Farshid TabbakhPlasma and Nuclear Fusion Research School, Nuclear Science and Technology Research Institute, Tehran, 14155-1339, Iran. ftabbakh2000@yahoo.com.
Narayan S HosmaneDepartment of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL, 60115-2862, USA.
Suffian M TajudinFaculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu, Malaysia.
Amir-Hossein GhorashiPlasma and Nuclear Fusion Research School, Nuclear Science and Technology Research Institute, Tehran, 14155-1339, Iran.
Nader MorshedianPlasma and Nuclear Fusion Research School, Nuclear Science and Technology Research Institute, Tehran, 14155-1339, Iran.
Atomic Energy Organization of Iran · IRNorthern Illinois University · USNuclear Science and Technology Research InstituteSultan Zainal Abidin University · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are two major problems in proton therapy. (1) In comparison with the gamma-ray therapy, proton therapy has only ~ 10% greater biological effectiveness, and (2) the risk of the secondary neutrons in proton therapy is another unsolved problem. In this report, the increase of biological effectiveness in proton therapy has been evaluated with better performance than

Indexed as

NanoparticlesProton TherapyCarbonDNAMonte Carlo MethodNeutronsProtonsRadiotherapy DosageCarbonDNAProtons

Identifiers

PMID36258012
PMCPMC9579128
OpenAlexW4306694118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.